Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant respiratory syncytial virus prefusion f protein antigen
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A recombinant prefusion-stabilized respiratory syncytial virus fusion glycoprotein antigen used as the active immunizing component of RSV vaccines. It is a **protein subunit biologic** designed to present the RSV F protein in its prefusion conformation, which exposes highly neutralization-sensitive epitopes and induces potent neutralizing antibody responses against RSV. In the provided context, this antigen corresponds to the active antigenic component used in GSK's RSVPreF3-based adult RSV vaccine program, where it is formulated with an adjuvant system to prevent RSV-associated lower respiratory tract disease and acute respiratory infection, particularly in older adults.
- Other names
- recombinant respiratory syncytial virus prefusion f protein antigenRSV prefusion F protein antigenprefusion RSV F glycoprotein antigen
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on recombinant respiratory syncytial virus prefusion f protein antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant respiratory syncytial virus prefusion f protein antigen.